{"transactions":[{"id":838695,"issuer":{"id":5811,"kind":"organization","name":"Corvex, Inc."},"owners":[{"id":60104,"kind":"person","name":"Wirk Shaheen","position":1,"cik":"0002050227","reported_name":"Wirk Shaheen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-03-17T18:01:25.000Z","date":"2026-03-13","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award was granted contingent upon shareholder approval of an amendment to the Omnibus Incentive Plan that increases the number of shares of Common Stock authorized for issuance under the Plan (the \"Plan Amendment\"). The option became exerciseable upon shareholder approval of the Plan Amendment on December 16, 2025."}],"balance_after":0,"derivative":{"exercise_price":1.25,"expiration_date":"2026-06-30","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001193125-26-111336","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050227/000119312526111336/ownership.xml","form_type":"4"}},{"id":838694,"issuer":{"id":5811,"kind":"organization","name":"Corvex, Inc."},"owners":[{"id":60104,"kind":"person","name":"Wirk Shaheen","position":1,"cik":"0002050227","reported_name":"Wirk Shaheen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-17T18:01:25.000Z","date":"2026-03-13","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":1.25,"value":12500.0,"ownership":{"direct":true},"balance_after":15960,"source":{"system":"sec-edgar","filing":"0001193125-26-111336","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050227/000119312526111336/ownership.xml","form_type":"4"}},{"id":941254,"issuer":{"id":5811,"kind":"organization","name":"Corvex, Inc."},"owners":[{"id":60104,"kind":"person","name":"Wirk Shaheen","position":1,"cik":"0002050227","reported_name":"Wirk Shaheen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-12T17:54:15.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":2980,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported transaction involved the reporting person's receipt of a grant of 2,980 RSUs under the Company's Omnibus Incentive Plan for the period January 1, 2026 to June 30, 2026."}],"balance_after":5860,"source":{"system":"sec-edgar","filing":"0001193125-26-010715","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050227/000119312526010715/ownership.xml","form_type":"4"}},{"id":941253,"issuer":{"id":5811,"kind":"organization","name":"Corvex, Inc."},"owners":[{"id":60104,"kind":"person","name":"Wirk Shaheen","position":1,"cik":"0002050227","reported_name":"Wirk Shaheen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-12T17:54:15.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":2980,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involved the reporting person's receipt of a grant of 2,980 restricted stock units (\"RSUs\") under the Company's Omnibus Incentive Plan in lieu of cash directors' fees for the period January 1, 2026 to June 30, 2026."}],"balance_after":2980,"source":{"system":"sec-edgar","filing":"0001193125-26-010715","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050227/000119312526010715/ownership.xml","form_type":"4"}},{"id":1003933,"issuer":{"id":5811,"kind":"organization","name":"Corvex, Inc."},"owners":[{"id":60104,"kind":"person","name":"Wirk Shaheen","position":1,"cik":"0002050227","reported_name":"Wirk Shaheen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-11-10T17:55:23.000Z","date":"2025-11-03","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option award was granted contingent upon shareholder approval of an amendment to the Omnibus Incentive Plan that increases the number of shares of Common Stock authorized for issuance under the Plan (the \"Plan Amendment\").  The option will become exerciseable upon shareholder approval of the Plan Amendment."}],"balance_after":10000,"derivative":{"exercise_price":1.25,"expiration_date":"2025-12-31","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001193125-25-274674","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050227/000119312525274674/ownership.xml","form_type":"4"}},{"id":1003932,"issuer":{"id":5811,"kind":"organization","name":"Corvex, Inc."},"owners":[{"id":60104,"kind":"person","name":"Wirk Shaheen","position":1,"cik":"0002050227","reported_name":"Wirk Shaheen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-10T17:55:23.000Z","date":"2025-11-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6841,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involved the reporting person's forfeiture of previously awarded restricted stock units (\"RSUs\") under the Company's Omnibus Inctive Plan (the \"Omnibus Incentive Plan\")  in lieu of directors' fees in exchange for the grant of stock options."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-274674","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050227/000119312525274674/ownership.xml","form_type":"4"}},{"id":1022373,"issuer":{"id":5811,"kind":"organization","name":"Corvex, Inc."},"owners":[{"id":60104,"kind":"person","name":"Wirk Shaheen","position":1,"cik":"0002050227","reported_name":"Wirk Shaheen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-07T09:24:46.000Z","date":"2025-10-03","kind":"grant","planned":false,"acquired":true,"shares":20685,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involved the reporting person's receipt of a grant of 20,685 restricted stock units (\"RSUs\") under the Company's Omnibus Incentive Plan in lieu of directors' fees for the period October 1, 2025 to December 31, 2025. The total reported in Column 5 consists solely of RSUs."}],"balance_after":68412,"source":{"system":"sec-edgar","filing":"0001193125-25-232768","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050227/000119312525232768/ownership.xml","form_type":"4"}},{"id":1092886,"issuer":{"id":5811,"kind":"organization","name":"Corvex, Inc."},"owners":[{"id":60104,"kind":"person","name":"Wirk Shaheen","position":1,"cik":"0002050227","reported_name":"Wirk Shaheen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-03T16:30:38.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":18657,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involved the reporting person's receipt of a grant of 18,657 restricted stock units (\"RSUs\") under the Company's Omnibus Incentive Plan in lieu of directors' fees for the period July 1, 2025 to September 30, 2025. The total reported in Column 5 consists solely of RSUs."}],"balance_after":47727,"source":{"system":"sec-edgar","filing":"0000950170-25-093920","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050227/000095017025093920/ownership.xml","form_type":"4"}},{"id":1151103,"issuer":{"id":5811,"kind":"organization","name":"Corvex, Inc."},"owners":[{"id":60104,"kind":"person","name":"Wirk Shaheen","position":1,"cik":"0002050227","reported_name":"Wirk Shaheen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-13T16:30:04.000Z","date":"2025-05-09","kind":"grant","planned":false,"acquired":true,"shares":29070,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involved the reporting person's receipt of a grant of 29,070 restricted stock units (\"RSUs\") under the Company's Omnibus Incentive Plan in lieu of directors' fees for the period October 1, 2024 to June 30, 2025."}],"balance_after":29070,"source":{"system":"sec-edgar","filing":"0000950170-25-070430","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050227/000095017025070430/ownership.xml","form_type":"4"}},{"id":1161421,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":60104,"kind":"person","name":"Wirk Shaheen","position":1,"cik":"0002050227","reported_name":"Wirk Shaheen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-02T18:12:20.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":263164,"ownership":{"direct":false,"nature":"Palkon TT Holdings, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The initial Form 4 inadvertently listed an incorrect transaction code."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Received in exchange for 1,962,199 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a Managing Manager of the Palkon Holdings LLC and Palkon TT Holdings LLC (the \"Palkon entities\"). The Reporting Person may be deemed to share the power to direct the disposition and vote of the shares held by the Palkon entities, but disclaims beneficial ownership, except to any pecuniary interests therein."}],"balance_after":263164,"source":{"system":"sec-edgar","filing":"0001415889-25-011857","document":"form4a-05022025_100517.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050227/000141588925011857/form4a-05022025_100517.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1161420,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":60104,"kind":"person","name":"Wirk Shaheen","position":1,"cik":"0002050227","reported_name":"Wirk Shaheen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-02T18:12:20.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":176030,"ownership":{"direct":false,"nature":"Palkon Holdings, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The initial Form 4 inadvertently listed an incorrect transaction code."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for 1,312,508 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a Managing Manager of the Palkon Holdings LLC and Palkon TT Holdings LLC (the \"Palkon entities\"). The Reporting Person may be deemed to share the power to direct the disposition and vote of the shares held by the Palkon entities, but disclaims beneficial ownership, except to any pecuniary interests therein."}],"balance_after":176030,"source":{"system":"sec-edgar","filing":"0001415889-25-011857","document":"form4a-05022025_100517.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050227/000141588925011857/form4a-05022025_100517.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1168518,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":60104,"kind":"person","name":"Wirk Shaheen","position":1,"cik":"0002050227","reported_name":"Wirk Shaheen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-21T17:15:15.000Z","date":"2025-04-17","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest and become exercisable over three years in 12 equal quarterly installments commencing on July 17, 2025, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":12000,"derivative":{"exercise_price":17.04,"expiration_date":"2035-04-16","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001415889-25-011111","document":"form4-04212025_050411.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050227/000141588925011111/form4-04212025_050411.xml","form_type":"4"}},{"id":1170018,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":60104,"kind":"person","name":"Wirk Shaheen","position":1,"cik":"0002050227","reported_name":"Wirk Shaheen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-17T18:50:13.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":2011,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Received in exchange for a stock option to acquire 15,000 shares of common stock of Legacy Tvardi with the exercise price of $0.09 per share pursuant the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Under the terms of the Merger, with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Tvardi common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Fully vested and exercisable."}],"balance_after":2011,"derivative":{"exercise_price":0.68,"expiration_date":"2031-01-29","underlying":"Common Stock","underlying_shares":2011},"source":{"system":"sec-edgar","filing":"0001415889-25-010980","document":"form4-04172025_060409.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2050227/000141588925010980/form4-04172025_060409.xml","form_type":"4"}},{"id":1170017,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":60104,"kind":"person","name":"Wirk Shaheen","position":1,"cik":"0002050227","reported_name":"Wirk Shaheen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-17T18:50:13.000Z","date":"2025-04-15","kind":"other","planned":false,"acquired":true,"shares":263164,"ownership":{"direct":false,"nature":"Palkon TT Holdings, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Received in exchange for 1,962,199 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Received in exchange for 1,962,199 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a Managing Manager of the Palkon Holdings LLC and Palkon TT Holdings LLC (the \"Palkon entities\"). The Reporting Person may be deemed to share the power to direct the disposition and vote of the shares held by the Palkon entities, but disclaims beneficial ownership, except to any pecuniary interests therein."}],"balance_after":263164,"source":{"system":"sec-edgar","filing":"0001415889-25-010980","document":"form4-04172025_060409.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050227/000141588925010980/form4-04172025_060409.xml","form_type":"4"}},{"id":1170016,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":60104,"kind":"person","name":"Wirk Shaheen","position":1,"cik":"0002050227","reported_name":"Wirk Shaheen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-17T18:50:13.000Z","date":"2025-04-15","kind":"other","planned":false,"acquired":true,"shares":176030,"ownership":{"direct":false,"nature":"Palkon Holdings, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Received in exchange for 1,312,508 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for 1,312,508 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a Managing Manager of the Palkon Holdings LLC and Palkon TT Holdings LLC (the \"Palkon entities\"). The Reporting Person may be deemed to share the power to direct the disposition and vote of the shares held by the Palkon entities, but disclaims beneficial ownership, except to any pecuniary interests therein."}],"balance_after":176030,"source":{"system":"sec-edgar","filing":"0001415889-25-010980","document":"form4-04172025_060409.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050227/000141588925010980/form4-04172025_060409.xml","form_type":"4"}},{"id":1170015,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":60104,"kind":"person","name":"Wirk Shaheen","position":1,"cik":"0002050227","reported_name":"Wirk Shaheen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-17T18:50:13.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":4191,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 31,252 shares of Series B Preferred Stock of  Tvardi Therapeutics, Inc. (\"Legacy Tvardi\") pursuant to Agreement and Plan of Merger and Reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\") and Legacy Tvardi, as amended (the \"Merger Agreement\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."}],"balance_after":4191,"source":{"system":"sec-edgar","filing":"0001415889-25-010980","document":"form4-04172025_060409.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050227/000141588925010980/form4-04172025_060409.xml","form_type":"4"}},{"id":1311304,"issuer":{"id":5811,"kind":"organization","name":"Corvex, Inc."},"owners":[{"id":60104,"kind":"person","name":"Wirk Shaheen","position":1,"cik":"0002050227","reported_name":"Wirk Shaheen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-01-06T16:29:52.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests in full on the one year anniversary of the grant date."}],"balance_after":10000,"derivative":{"exercise_price":5.28,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000950170-25-002172","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050227/000095017025002172/ownership.xml","form_type":"4"}},{"id":1311303,"issuer":{"id":5811,"kind":"organization","name":"Corvex, Inc."},"owners":[{"id":60104,"kind":"person","name":"Wirk Shaheen","position":1,"cik":"0002050227","reported_name":"Wirk Shaheen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-01-06T16:29:52.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":13300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted on 1/2/2025 pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest and become exercisable in forty-eight equal monthly installments beginning on the date that is one month following the grant date; provided that immediately prior to, and contingent upon, a change in control, the options will become fully vested and exercisable."}],"balance_after":13300,"derivative":{"exercise_price":5.28,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":13300},"source":{"system":"sec-edgar","filing":"0000950170-25-002172","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050227/000095017025002172/ownership.xml","form_type":"4"}}]}